Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bayer AG is conducting a first-in-human clinical study titled A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of BAY 3713372, a Novel 2nd Generation PRMT5 Inhibitor, in Participants With MTAP-deleted Solid Tumors. The study aims to assess the safety and optimal dosing of BAY 3713372, a drug targeting MTAP-deleted solid tumors by inhibiting PRMT5, potentially sparing normal cells while targeting cancerous ones.
The intervention being tested is BAY 3713372, administered orally, designed to treat MTAP-deleted solid tumors by blocking PRMT5, which may result in the death of cancer cells.
The study follows an interventional design with a sequential intervention model, focusing on treatment. There is no masking involved, meaning both participants and researchers know the treatment being administered.
The study began on March 21, 2025, with an estimated primary completion date yet to be announced. The last update was submitted on August 14, 2025, indicating ongoing recruitment and progress.
For investors, this study could impact Bayer’s stock performance positively if the results demonstrate safety and efficacy, potentially positioning Bayer ahead of competitors in the oncology market. The absence of masking and the study’s early phase suggest initial findings will be crucial for future developments.
The study is currently recruiting, with further details available on the ClinicalTrials portal.